Literature DB >> 11642497

Intensive immunoablation and autologous blood stem cell transplantation in patients with refractory rheumatoid arthritis: the University of Nebraska experience.

S Z Pavletic1, J R Odell, S J Pirruccello, M M Ursick, C E Haire, J G Sharp, A Kessinger, L W Klassen.   

Abstract

Two patients with severe rheumatoid arthritis (RA) were treated with high dose chemotherapy and autologous blood stem cell transplantation. Hematopoietic stem cells mobilized readily with cyclophosphamide and granulocyte-colony stimulating factor. Both patients achieved an American College of Rheumatology (ACR) 50% response before starting high dose therapy. The transplantation regimen included 200 mg/kg cyclophosphamide and 6 doses of equine antithymocyte globulin. Transplantation was well tolerated and both patients recovered neutrophils on day 7 post-transplant. At one month post-transplant both patients had an ACR response of 80%. Both individuals relapsed at 6 months and responded well to a combination of disease modifying antirheumatic drugs that was previously ineffective. At 12 months ACR responses were 80% and 60%, respectively. The first patient developed a flare at 18 months when she was found to be hypothyroid; she regained an 80% ACR response at 24 months with therapy of hypothyroidism. The second patient progressed relentlessly 15 months post-transplant. Immunological reconstitution showed a continuous inversion of the ratio of CD4 and CD8 lymphocytes with a predominant expansion of memory T cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11642497

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  1 in total

1.  Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration.

Authors:  R J Verburg; R Flierman; J K Sont; F Ponchel; L van Dreunen; E W Levarht; M M Welling; R E M Toes; J D Isaacs; J M van Laar
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.